Shield Therapeutics plc (LON:STX – Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 9.39 and traded as low as GBX 7.50. Shield Therapeutics shares last traded at GBX 7.75, with a volume of 5,318,340 shares.
Shield Therapeutics Stock Down 3.1%
The stock has a market cap of £92.65 million, a P/E ratio of -4.34 and a beta of 1.91. The company has a current ratio of 0.83, a quick ratio of 2.16 and a debt-to-equity ratio of -182.06. The firm’s fifty day moving average is GBX 9.32 and its 200 day moving average is GBX 9.03.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Stories
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
